🎗️ OncologyInjection (IV)
Carvykti
Ciltacabtagene Autoleucel
BCMA-directed CAR T-cell therapy for relapsed/refractory multiple myeloma after prior lines of therapy.
Form
Injection (IV)
Uses
1
Side effects
5
Category
Oncology
01
What is Carvykti used for?
- Relapsed/refractory multiple myeloma
02
Ciltacabtagene Autoleucel side effects
The following side effects have been reported for Ciltacabtagene Autoleucel. Their order does not indicate how often an effect occurs.
Cytokine release syndrome
Neurotoxicity (ICANS)
Infections
Cytopenias
Movement disorders
03
Ciltacabtagene Autoleucel warnings & precautions
- Black box: CRS, neurotoxicity, HLH/MAS, prolonged cytopenias, and secondary T-cell malignancies
- REMS required
- Only at certified centers
Loading FDA data…
04
Frequently asked questions
05
Related medications
Share
Share this drug info.
Help friends and family understand Carvykti in plain language.
Disclaimer: This information is sourced from the FDA openFDA database and is provided for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before starting or changing medication.